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Objectives. This study sought o determine whether dobutamine 
stress echocardiography could accurately identify coronary artery 
disease after heart ransplantation. 
Background. After heart ransplantation, coronary artery dis- 
ease is related to either diffuse concentric intimal thickening or 
focal stenosis and may be underdiagnosed by coronary angiography. 
Methods. We enrolled 41 patients, a mean (-+SD) of 40 -+ 20 
months after heart ransplantation, at the time of their routine 
control coronary angiogram. Three patients were excluded be- 
cause of poor echogenicity on the angiogram and one because of 
ventricular premature beats. Standard echocardiographic v ews 
were acquired at baseline and at incremental dobutamine infusion 
levels (from 5 to a maximal dose of 40/xg/kg body weight per min 
at 3-rain intervals). Regional wall motion score was calculated 
from a 16-segment model, and each segment was graded from 1 
(normal) to 4 (dyskinesia). Coronary angiography was performed 
24 h after dobutamine stress echocardiography, and angiograms 
were analyzed in blinded manner. 
Results. Twenty-three (62%) of 37 patients had normal coro 1 
nary angiographic findings. Dobutamine stress echocardiography 
showed abnormalities in only 2 of 23 patients. Fourteen patients 
(38%) had abnormal angiographic findings, seven of whom had 
stenoses >50%. Dobutamine stress echocardiography correctly 
identified the corresponding hypoperfused segments in these 
seven patients. More of interest were the other seven patients, of 
whom three had angiographic nonsignificant stenoses (<50%), 
and four had minor diffuse coronary irregularities. Dobutamine 
stress echocardiography s owed hypokinesia nfive of these seven 
patients despite nonsignificant lesions at coronary angiography. 
The respective overall sensitivity and specificity of dobutamine 
stress echocardiography were 86% and 91%. At follow-up, 2of the 
37 patients had an acute myocardial infarction. Both had abnor- 
mal findings on dobutamine stress echocardiography: One had 
normal coronary angiographic results, and one had significant 
coronary lesions. 
Conclusions. Dobutamine stress echocardiography is a useful 
technique for the diagnosis of coronary artery disease after heart 
transplantation. These preliminary results indicate that dobut- 
amine stress echocardiography may have a predictive value for 
further ischemic events in heart ransplant recipients. 
(JAm Coil Cardio11995;25:1665-72) 
Cardiac transplantation is a common treatment for end-stage 
heart disease. Because the treatment of early rejection by 
cyclosporine has increased survival, coronary artery disease has 
become the leading cause of morbidity and mortality after 
heart transplantation (1). 
The heterogeneity of coronary artery disease after trans- 
plantation has been stressed by the Stanford group after 
sequential coronary angiography (2) and in a pathologic exam- 
ination performed in the first year after transplantation (3). In 
transplant vasculopathy, two types of coronary artery lesions 
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may be recognized (2-5): either diffuse, concentric, homoge- 
neous lesions related to a fibrous intimal hyperplasia (3) or 
focal stenosis quite similar to native atherosclerotic vessel 
disease. Nonquantitative coronary angiographic methods un- 
derestimate he incidence and severity of the diffuse concentric 
lesions as assessed by histopathologic (6) and intracoronary 
ultrasound (7) studies and have been shown to be insensitive 
for assessment of progression of coronary narrowing after 
transplantation (8). The systematic use of quantitative angiog- 
raphy provides a more sensitive method for assessing subtle 
reduction in lumen diameter (8) and is therefore useful in 
tracking the progression of coronary lumen narrowing. 
Currently, noninvasive tests for ischemia (i.e., exercise 
stress test, echocardiography, rest/exercise gated wall motion, 
dipyridamole thallium, Holter) (9,10) have shown low sensitiv- 
ity and low predictive value for detecting coronary artery 
disease after cardiac transplantation. Dobutamine stress echo- 
cardiography as been demonstrated to be an accurate method 
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for detecting ischemia in native coronary artery disease (11- 
14), but its value in heart transplantation is not yet widely 
established. The aim of the present study was to evaluate the 
accuracy and predictive value of dobutamine stress echo- 
cardiography in detecting coronary artery disease after heart 
transplantation. 
Methods 
Patients. From 106 heart ransplant recipients, we enrolled 
41 consecutive patients, a mean (_+SD) of 40 _+ 20 months 
after transplantation, at the time of their routine control 
coronary angiogram. (34 men, 7 women; mean age 52 _+ 12 
years, range 24 to 68). All patients gave written informed 
consent. Patients received astandard immunosuppressive pro- 
tocol, including cyclosporine, azathioprine and prednisone. 
Additionally, all patients received from the first postoperative 
week antiplatelet therapy with either aspirin (100 mg daily) or 
dipyridamole (225 mg daily). Of these 41 patients, 21 had 
systemic hypertension and received either calcium or beta- 
adrenergic blocking agents. At the time of the study, a previous 
posterior myocardial infarction had occurred in one patient 
since heart ransplantation. 
Cardiac catheterization. Selective coronary angiography, 
left ventriculography, right heart catheterization a d endo- 
myocardial biopsy were initially performed 18 months after 
transplantation. Thereafter, outine invasive studies were re- 
peated at 18-month intervals. All patients were free of acute 
rejection at the time of coronary angiogram. 
Single-plane coronary angiograms were obtained with a 
standard cineangiographic system interfaced to a digital radio- 
graphic computer system (DCI Philips system). Quantitative 
angiographic measurements of percent diameter stenosis and 
minimal umen diameter were performed using the single cine 
images that best demonstrated a stenosis in the coronary artery 
at its most severe narrowing. From this quantitative analysis, 
three groups of patients could be determined: Group 1 = 
patients with normal coronary angiographic findings. No an- 
giographic evidence of focal stenosis or diffuse irregularities 
was observed in any of these patients. Group 2 = patients with 
coronary artery lesions without significant lumen narrowing 
(i.e., <50%). These patients had either discrete focal stenosis 
or minor diffuse irregularities pread uniformly along the 
length of the coronary artery or present only in proximal, 
middle or distal major coronary segments. Group 3 = patients 
with coronary artery lesions with significant lumen narrowing 
(i.e., ->50%). These patients had severe focal stenosis or 
diffuse irregularities present in proximal, middle or distal 
major coronary segments. 
The coronary angiograms were all recorded with the same 
catheter size, magnification and views. They were analyzed by 
two independent cardiologists unaware of the patient's clinical 
status. 
Dobntamine infusion protocol. All patients underwent do- 
butamine stress echocardiography within 1 month of cardiac 
catheterization. Beta-blocker therapy was stopped 48 h before 
the test, whereas calcium antagonists were not discontinued. 
Dobutamine was infused in increments beginning with a dose 
of 5/xg/kg body weight per rain and increasing by 5 ~g/kg per 
rain every 3 rain up to a maximal dose of 40/~g/kg per rain. 
Electrocardiographic (ECG) monitoring was performed 
throughout, with a 12-lead ECG and blood pressure recorded 
at the end of each stage. End points to terminate the dobut- 
amine infusion were: 1) a new abnormality of regional wall 
motion in two or more contiguous egments; 2) target heart 
rate (defined as 85% of the age-predicted maximal heart rate); 
3) _>2 mm of horizontal or downsloping ST segment depres- 
sion on the ECG; 4) systolic blood pressure >220 mm Hg or 
diastolic blood pressure >110 mm Hg; 5) _>15 mm Hg decline 
in systolic blood pressure; 6) maximal dose of 40/xg/kg per 
rain; 7) significant side effects or arrhythmia. 
Eehoeardiography. Echocardiograms were obtained with 
commercially available quipment (Acuson XP 128) equipped 
with a 2.5-MHz transducer. Four views of the left ventricle 
(parasternal long- and short-axis, apical four- and two- 
chamber views) were recorded at baseline and during each 
stage of dobutamine infusion on videotape. Images at baseline, 
low dose (5/~g/kg per rain), peak dose and 5 rain into recovery 
were transferred in digital form for display as continuous loop 
images in a quad screen format (Freeland Systems) and stored 
on a floppy disk. In all studies, the videotape was reviewed in 
addition to the digitized images. Echocardiographic wall mo- 
tion was graded as follows: 1 = normal or hyperkinetic; 2 = 
hypokinetic; 3 = akinetic; 4 = dyskinetic. A 16-segment model 
was used for grading wall motion. A wall motion score index 
was derived for baseline, low dose and peak dose echocardio- 
grams in each patient. The wall motion score was derived by 
summation ofindividual segment scores divided by the number 
of interpreted segments. Inadequately visualized segments 
were not scored. An individual study was defined as technically 
difficult if more than two segments could not be adequately 
visualized. All dobutamine stress echocardiograms were inde- 
pendently interpreted by two trained echocardiographers in 
blinded manner without knowledge of clinical status, ECG 
response during infusion or coronary angiography. A third 
investigator reviewed the echocardiograms in blinded manner 
if the first two investigators were not in agreement. 
Negative or normal dobutamine stress echographic findings 
were defined as a progressive increase in wall motion and 
myocardial thickening during dobutamine infusion. Positive or 
abnormal dobutamine stress echocardiographic f ndings were 
defined as a reduction or a lack of increase in systolic thick- 
ening. For studies without wall motion abnormalities at rest, 
any new dobutamine-induced wall motion abnormality was 
considered a positive finding. For studies with baseline wall 
motion abnormalities, the development of new or worsening 
regional asynergy, deteriorating from hypokinesia to akinesia 
or dyskinesia during dobutamine infusion, was considered an 
abnormal finding. 
Stress test. Exercise ECGs were obtained in 33 study 
patients at the time of coronary angiography and dobutamine 
stress echocardiography. The stress test was performed on a 
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supine bicycle rgometer using a protocol of stepwise increases 
in work beginning at 30 W and increasing by 10 W every 
minute. During exercise, blood pressure was monitored at 
2-min intervals, and the ECG was constantly monitored 
throughout the test. The exercise test result was considered 
positive if ST segment depression > 1 mm occurred 0.08 s after 
the J point. 
Statistical nalysis. The sensitivity and specificity of dobut- 
amine stress echocardiography for detection of coronary 
artery disease was determined by quantitative coronary angiog- 
raphy as the reference positive standard. These values were 
determined using standard formulas: Sensitivity -- True 
positive/(True positive + False negative); Specificity = True 
negative/(True negative + False positive); and Positive predic- 
tive value = True positive/(True positive + False positive); 
Negative predictive value = True negative/(False negative + 
True negative.) 
Results are expressed as mean value _+ SD. Statistical 
analysis was performed using a Student t test for paired data or 
chi-square test when indicated. Numerical data from multiple 
groups were compared using analysis of variance followed 
when significant by a Fisher test. Hemodynamic responses to 
dobutamine infusion (i.e., heart rate, systolic and diastolic 
blood pressures, rate-pressure product) were analyzed using 
repeated-measures analysis of variance. A p value <0.05 was 
considered significant. 
Results 
Feasibility of the study. Dobutamine stress echocardiogra- 
phy was performed in 37 of 41 patients. Three of 41 patients 
were excluded because of poor echogenicity, and dobutamine 
stress echocardiography was prematurely interrupted in an- 
other (15/~g/kg per mn) because of ventricular ectopic activity. 
Rest and stress echocardiograms were of adequate quality for 
interpretation in the remaining 37 patients. Two patients had 
technically difficult studies (parasternal tong- and short-axis 
views could not be easily obtained) but were not excluded 
because their studies were judged to be of adequate quality for 
interpretation 14 of 16 segments. In these two patients, the 
angiographic and echocardiographic results correlated. Both 
had distal left anterior descending coronary artery irregulari- 
ties and subsequent apical hypokinesia during d0butamine 
infusion. 
Complete agreement between the two observers was 
achieved in 92% (34 of 37) of the studies. The two investigators 
disagreed on the presence or absence of a stress-induced 
abnormality in only one patient, and a third unaware, blinded 
investigator concluded that this patient had positive dobut- 
amine echocardiographic f ndings. In two studies, there was 
disagreement regarding the extent of rest wall motion abnor- 
malities. One observer ead each study twice, with agreement 
between the two readings in 95% (35 of 37) of the studies. 
Demographic characteristics. Patient characteristics in the 
three angiographic subgroups are presented in Table 1. No 
Table 1. Clinical Characteristics of 37 Study Patients 
Group 1 Group 2 Group 3 
(n = 23) (n = 7) (n = 7) 
Recipient age (yr) 51 + 13 47 _+ 16 57 _+ 6 
Donor age (yr) 31 -+ 9 37 -+ 11 33 -+ 8 
Time from HTX (too) 39 -+ 19 46 _+ 21 37 _+ 23 
EF (%) 67 _+ 7 65 -+ 7 62 _+ 8 
Rejection episode 1.9 -+ 2.4 2.6 _+ 2.9 2.6 _+ 1.9 
Indications for HTX 
DCM 18 4 3 
CAD 3 3 3 
Valvular HD 2 0 1 
Dyslipidemia 6 (34%) 3 (43%) 6 (86%) 
Systemic hypertension 13 (56%) 3 (43%) 5 (71%) 
CMV infection 10 (43%) 4 (57%) 3 (43%) 
p = NS for all three groups for all variables except dyslipidemia, which was 
significantly higher (p < 0.05) in groups 2 and 3 combined than in group 1 alone. 
Data presented are mean value _+ SD or number (%) of patients. CAD = 
coronary artery disease; CMV = cytomegalovirus; DCM = dilated cardiomyop- 
athy; EF = ejection fraction; Group 1 = normal angiographic findings; Group 2 = 
<50% diameter stenosis; Group 3 = _>50% diameter stenosis; HD = heart 
disease; HTX = heart transplantation. 
statistical difference was noted between the groups for the 
following variables: recipient and donor age, donor ischemic 
time, recipient's native heart disease, time elapsed since trans- 
plantation, number of acute rejection episodes, systemic hy- 
pertension, cytomegalovirus infection in the recipient and 
mean plasma triglyceride, high density lipoprotein cholesterol 
and fasting blood glucose levels. Patients with coronary artery 
disease had higher levels of total plasma cholesterol than those 
with normal coronary angiographic findings (273 _+ 58 vs. 
233 _+ 43 mg/dl, p < 0.02), as well as higher levels of low 
density lipoprotein cholesterol (193 +_ 54 vs. 141 _+ 48 mg/dl, 
p < 0.02). 
Cardiac catheterization. Coronary angiographic results 
were normal in 23 (group 1) (62%) of the 37 patients tudied 
and showed neither focal stenosis nor diffuse irregularities. In 
group 1, mean minimal umen diameter was 2.3 _+ 0.4 mm. 
Coronary artery disease was present in the remaining 14 
patients (38%): 7 with one-vessel, 3 with two-vessel and 4 with 
three-vessel disease. Coronary artery narrowing was nonsignif- 
icant in seven patients (Group 2) and significant in seven 
(group 3). Angiographic (diseased coronary vessel and values 
for percent diameter stenosis) and echocardiographic charac- 
teristics of these 14 patients are presented in Table 2. 
In group 2, mean minimal lumen dimension of angiographi- 
cally normal segments was 2.2 _+ 0.4 mm (p = NS vs. group 1). 
Isolated iscrete focal stenoses were observed in two patients: 
one 33% mid-left anterior descending stenosis and one 20% 
right coronary artery at the second segment. Minor diffuse 
irregularities without focal stenosis were observed in four 
patients, involving the distal right coronary artery in one 
(minimal umen diameter 1.8 mm [15% stenosis]), mid- and 
distal left anterior descending coronary artery in another 
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Table 2. Coronary Angiographic and Dobutamine Stress Echocardiographic Results for Patients With Nonsignificant and Significant 
Coronary Lesions 
Pt Age (yr)/ Vessel Diseased 
No. Gender (% stenosis) 
Baseline Asynergy Peak Asynergy 
DSE Score Segment Score Segment 
Group 2: Patients With Nonsignificant Coronary Lesions 
1 49/M LAD (33%) Positive 1.57 Ant 2.14 Ant, Apex 
2 64/M LAD (mid 25%, distal 30%) Positive 1 - -  1.43 Ant 
3 59/F RCA (20%) Positive 1 - -  1.5 Inf 
4 34/M RCA (15%) Positive 1 - -  1.5 Inf 
5 54/M RCA (18%), LCx (40%) Negative 1 - -  1 - -  
6 20/M RCA (22%), LAD (15%) Positive 1.43 Ant 1.86 Ant, Sept 
7 61/M RCA (35%), LAD (20%), LCx (30%) Negative 1 - -  1 - -  
Group 3: Patients With Significant Coronary Lesions 
1 57/F RCA (62%) Positive 1 - -  1.5 Inf 
2 49/M LAD (mid 52%, distal 100%) Positive 1.5 Apex 1.86 Ant, Apex 
3 58/M RCA (57%) Positive 1 - -  1.5 Inf 
4 66/M LAD (52%), LCx (82%) Positive 1 - -  1.14 Apex 
5 57/M LAD (44%), LCx (83%), RCA (18%) Positive 1.64 Inf 1.78 Ant, Inf 
6 56/M LAD (58%), LCx (91%), RCA (22%) Positive 1.3 Apex 1.5 Ant, Apex, Sept 
7 64/M LAD (100%), LCx (72%), RCA (93%) Positive 2.33 Ant, Sept 2.6 Ant, Apex, Sept 
Ant - anterior; DSE = dobutamine stress echocardiography; F = female; Inf = inferior; LAD : left anterior descending coronary artery; LCx : left circumflex 
coronary artery; M = male; RCA = right coronary artery; Sept = interventricular septum. 
(respective minimal lumen diameters 2.1 and 1.6 mm [25% and 
30% stenosis]), proximal eft anterior descending and mid- 
right coronary arteries in one (respective minimal lumen 
diameters 2.9 and 2.2 mm [15% and 22% stenosis]) and distal 
left anterior descending, left circumflex and right coronary 
arteries in one (respective minimal lumen diameters: 2, 1.8 and 
1.7 mm [20%, 35% and 30% stenosis]). In one patient in group 
2, a 40% focal stenosis on the marginal artery was associated 
with diffuse irregularities in the mid- and distal right coronary 
artery. 
In group 3, mean minimal lumen dimension of angiographi- 
cally normal segments was 1.9 _+ 0.6 mm (p = NS vs. group 1). 
Significant focal stenoses (>50% narrowing) were observed in 
the seven patients. Diffuse irregularities predominating in the 
distal portion of epicardial coronary arteries were present in all 
patients. These irregularities were moderate in five patients 
and severe in two with a distal left anterior descending 
coronary artery obliteration. 
Dobntamine stress echoeardiography. The maximal dose 
of dobutamine was similar in groups 1 to 3, respectively: 29 _+ 
6, 29 _ 5 and 31 _+ 8. None of the patients developed ischemia 
on ECG monitoring during the dobutamine infusion. 
The main reasons for terminating the dobutamine infusion 
were achievement of target heart rate (29 patients [78%]), 
maximal dose (2 patients [5%]), wall motion abnormalities (2
patients [5%]) and decrease in systolic blood pressure (3 
patients [8%]). Wall motion score index was normal at baseline 
in group 1 and remained unchanged atpeak dobutamine dose 
(1 vs. 1.02 __ 0.06, p = NS). Baseline wall motion score was 
abnormal in two of seven patients in group 2 and four of seven 
in group 3 (Table 2); it was significantly higher in group 3 (p < 
0.01). Wall motion score increased from 1.14 __ 0.25 to 1.49 _+ 
0.42 (p < 0.01) in group 2 and from 1.39 _+ 0.49 to 1.70 _+ 0.46 
(p < 0.01) in group 3. Dobutamine stress echocardiographic 
findings were positive in 12 of the 14 patients with coronary 
artery disease (overall sensitivity 86%), in all seven patients 
with sign!ficant coronary artery disease (group 3) and in five of 
the seven patients with nonsignificant lesions (group 2). Do- 
butamine stress echocardiographic findings were negative in 21 
of 23 patients without coronary artery disease (specificity 
91%). The positive predictive value of the test was 86%, the 
negative predictive value 91%. 
One of the patients with results considered false positive 
because of normal coronary angiographic and positive dobut- 
amine stress echocardiographic f ndings developed an acute 
anterior myocardial infarction 3 months later, when dobut- 
amine stress echocardiography demonstrated septal and ante- 
rior hypokinesia. One of the patients with significant (three- 
vessel disease) coronary lesions (83% focal stenosis in the 
proximal circumflex, 44% stenosis in the mid-left anterior 
descending and two 20% stenoses in the proximal and mid- 
right coronary arteries) had an ischemic ardiac arrest during 
a bicycle stress test performed 3 months after the coronary 
angiogram and could not be resuscitated. 
Only four patients had positive bicycle stress test results 
with ST segment depression on the ECG. These four patients 
had coronary artery disease with significant coronary narrow- 
ing (two had three-vessel, two had two-vessel disease). 
Hemodynamic response to dobutamine infusion. Figure 1 
compares hemodynamic variables at baseline and peak dose, 
and Figure 2 compares the same variables at each dose of 
dobutamine in the three study groups: heart rate (Fig. 1A and 
2A) increased significantly (p < 0.001), and maximal heart rate 
was similar in all three groups: 159 + 13, 153 _+ 20 and 145 _ 
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Figure 1. Heart rate, systolic and 
diastolic blood pressures (BP) and 
rate-pressure product at baseline 
(Base) and at peak dobutamine 
dose in patients with normal 
coronary angiographic findings 
(group 1 [open bars]) and nonsig- 
nificant (<50% diameter stenosis, 
group 2 [solid bars[) and signifi- 
cant coronary lesions (->50% di- 
ameter stenosis, group 3 [hatched 
bars]). 
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21 beats/rain in groups 1 to 3, respectively. Heart rate in- 
creased progressively during dobutamine infusion with no 
tendency to plateau except in group 3. Systolic blood pressure 
(Fig. 1B and 2B) increased nonsignificantly in groups 1 and 2 
but showed atrend toward decrease ingroup 3. Diastolic blood 
pressure (Fig. 1C and 2C) decreased significantly (p < 0.01) in 
groups 1 and 3 and nonsignificantly in group 2. Rate-pressure 
product (Fig. 1D and 2D) increased significantly in the three 
groups (p < 0.001), with a tendency to plateau in group 3. 
However, repeated-measures analysis of variance showed no 
significant difference among the three groups in hemodynamic 
responses at each dobutamine infusion level. When the phys- 
iologic variables obtained at baseline and at the end stage 
dobutamine stress echocardiography and exercise stress tests 
were compared in all patients and in each study group alone 
(Fig. 3), peak heart rate was significantly higher (p < 0.001) 
during dobutamine infusion than during exercise, whereas 
peak systolic blood pressure was significantly higher during 
exercise. This resulted in a higher rate-pressure product 
during exercise than during dobutamine infusion, except in 
group 2, where peak systolic blood pressure was not signifi- 
cantly higher during exercise, which resulted in a significantly 
lower rate-pressure product (p < 0.05) at peak exercise. In all 
patients and in each group, diastolic blood pressure increased 
Figure 2. Changes in heart rate, systolic and diastolic blood 
pressures (BP) and rate-pressure product during dobut- 
amine infusion in the three groups of study patients. 
Circles = patients with normal findings; squares = patients 
with nonsignificant coronary lesions; triangles = patients 
with significant coronary lesions. 
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Figure 3. Heart rate, systolic and diastolic blood 
pressures (BP) and rate-pressure product at peak 
dobutamine dose (solid bars) and peak exercise 
(hatched bars) in patients with normal coronary 
angiographic findings (Group I) and nonsignificant 
(Group II) and significant (Group III) coronary 
lesions. *p < 0.05. **p < 0.01. ***p < 0.001. 
during exercise and was significantly higher than that during 
dobutamine at the end stage of the test. 
Adverse effects. No major complications occurred during 
dobutamine infusion. Nonsustained supraventricular t chycar- 
dia occurred in two patients and premature ventricular beats in 
one at a 15-/xg/kg per min dose. Dizziness without significant 
decrease in systolic blood pressure occurred in one patient, 
and the test was ended at 25 txg/kg per min. No chest pain was 
observed. 
Discuss ion  
Diagnosis of posttransplant coronary artery disease. Cor- 
onary artery vasculopathy after heart transplantation has 
emerged as a major cause of morbidity and mortality in 
long-term heart transplant survivors and is the most common 
indication for retransplantation (1,15). Because of autonomic 
denervation, transplant recipients generally do not experience 
angina pectoris. Therefore, posttransplant coronary artery 
disease may present as silent myocardial infarction, congestive 
heart failure or ventricular arrhythmia. This raises the problem 
of the best methods of diagnosis of posttransplant coronary 
artery disease. 
Existing studies rely on conventional coronary arteriogra- 
phy. The angiographic incidence of coronary artery disease has 
been reported to range from 2% to 28% at 1 year after 
transplantation (16,17), increasing to 40% to 70% by 5 years 
(18-20). The pathogenesis remains unclear, and many factors 
have been advocated as being associated with the development 
of coronary artery disease. Besides a higher incidence of acute 
myocardial rejection episodes (20), cytomegalovirus infection 
(21), systemic hypertension (18) and hyperlipidemia (22,23) 
are important factors in the development ofcoronary occlusive 
disease. In our series, dyslipidemia (i.e., elevated total choles- 
terol and low-density lipoprotein levels) was the only factor 
significantly different between patients with and without coro- 
nary artery disease. Graft atherosclerosis often differs from 
conventional atherosclerosis because besides proximal focal 
stenosis similar to that of common atherosclerotic lesions, 
extensive diffuse obliterative l sions of distal vessel segments 
are also seen. Most of the recipients have only minimal umen 
irregularities, which may represent an early stage of posttrans- 
plant coronary artery disease. 
To take into account hese minor lesions, usually consid- 
ered nonsignificant by quantitative coronary angiography, an- 
giographic findings were considered abnormal when even 
minor lumen irregularities were present. Therefore, we classi- 
fied the coronary artery disease into three groups: normal 
arteries and nonsignificant and significant lesions. Despite the 
improved sensitivity of quantitative angiography in detecting 
smooth concentric vessel narrowing, coronary angiography 
consistently underdiagnoses graft coronary artery disease and 
underestimates its severity. Although histologic and nonquan- 
titative angiographic omparisons of the degree of lumen 
narrowing show good correlation for severe stenoses, Johnson 
et al. (6) demonstrated that lesions graded with <25% diam- 
eter narrowing are often underestimated angiographically 
compared with histologic determinations. Intracoronary ultra- 
sound enables more accurate assessment of smooth concentric 
stenoses, but the size of the probe restricts its use to large 
epicardial vessels (7). The widespread involvement of small 
vessels in posttransplant coronary artery disease probably 
limits the accuracy of coronary angiography and intracoronary 
ultrasound. 
Functional assessment by traditional noninvasive tests has 
proved disappointing, with a low sensitivity for routine use. 
Smart et al. (9) indicated a sensitivity ranging from 21% for 
routine treadmill tests and dipyridamole thallium tests to 56% 
for Holter monitoring and 58% for baseline chocardiographic 
wall motion study. Other studies (10,24) report he poor value 
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of exercise thallium scintigraphy in detecting raft coronary 
artery disease. 
Dobutamine stress eehocardiography. Since dobutamine 
was first used as a cardiac stress agent in 1984 (25), the use of 
dobutamine stress testing in ischemic heart disease has dra- 
matically increased, and dobutamine stress echocardiography 
has been proposed as a clinically useful noninvasive test for 
evaluation of patients with native coronary artery disease 
(11-14). Dobutamine (26) is a stimulator of beta1-, beta 2- and 
alphal-adrenoreceptors with more inotropic effects than chro- 
notropic activity. These effects are dose dependent, with 
increased contractility predominating atlower doses and pro- 
gressive tachycardia at higher doses. In patients with coronary 
artery disease, dobutamine induces ischemia by increasing left 
ventricular contractility, heart rate and wall stress (27). There- 
fore, dobutamine stress test better approximates xercise than 
does dipyridamole through a progressive stepwise stress with a 
consistent increase in rate-pressure product and myocardial 
oxygen demand (28,29). Dobutamine can be administered 
safely (30) and has a rapid onset and cessation of action. Recent 
reports found dobutamine stress echocardiography to be highly 
sensitive and specific for detecting coronary artery disease. Sen- 
sitivity and specificity were, respectively, 86% and 95% for Cohen 
et al. (31), 89% and 85% for Sawada et al. (11) and 78% and 93% 
for Mazeika et al. (12). 
Present study. The value of dobutamine stress echocardi- 
ography in the detection of coronary lesions in heart ransplant 
recipients has not yet been widely established. Our results 
clearly demonstrate he accuracy of this method, giving a high 
overall sensitivity (86%) and specificity (91%) in the detection 
of graft coronary artery disease. These results are consistent 
with studies performed in non-heart transplant recipients. All 
patients with significant stenosis had positive dobutamine 
stress echocardiographic f ndings. More of interest is the 
finding that dobutamine stress echocardiography remained 
sensitive enough (71%) even when coronary lesions were 
considered nonsignificant (<50% narrowing) by quantitative 
analysis of coronary angiograms. Results from another dobut- 
amine stress echocardiographic study (32) in 41 heart trans- 
plant recipients are consistent with our data. Of the 21 patients 
with angiographic oronary artery disease, 20 had positive 
dobutamine stress echocardiographic findings (sensitivity 
95%), whereas of the 20 patients with normal coronary anglo- 
graphic findings, 9 had positive dobutamine stress echocardio- 
graphic results (specificity 55%). 
In the present study, two patients with positive dobutamine 
stress echocardiographic findings had a major cardiac event 
during the following 6 months: One had significant coronary 
artery disease and died after an ischemic ardiac arrest during 
an exercise test; the other had an acute anterior myocardial 
infarction despite normal coronary angiographic findings 3 
months earlier. No cardiac event was noted in patients with 
negative dobutamine stress echocardiographic results. This 
observation may strongly suggest the prognostic significance of 
positive findings on dobutamine stress echocardiography de- 
spite the small number of patients enrolled in this series and 
hence requires further studies for confirmation. 
Dobutamine induced a significant increase in heart rate in 
the three groups of patients. However, in patients with signif- 
icant coronary lesions, heart rate increased with a tendency to 
plateau. Systolic blood pressure tended to increase in patients 
with normal findings on coronary angiography and nonsignif- 
icant lesions but to decrease inpatients with significant lesions. 
Rate-pressure product significantly increased in the three 
groups but also showed a plateau in group 3. The importance 
of the blunted hemodynamic response as an indicator of 
myocardial ischemia has been previously reported in nontrans- 
plant recipients (31). Our data suggest that in heart transplant 
recipients, a plateau in heart rate, systolic blood pressure and 
rate-pressure product during dobutamine infusion should be a 
predictor of severe stenosis. The failure of systolic blood 
pressure to increase in patients with significant coronary 
lesions could be related to a decreased peak ejection fraction. 
We could not, unfortunately, document it by quantitative 
analysis of myocardial function, which should have theoreti- 
cally enabled a step-by-step determination of left ventricular 
ejection fraction. However, this quantitative approach during 
dobutamine infusion is disappointing, as shown by other 
workers (33) for technical problems related to the cardiac 
translation and rotation and to the exaggerated hyperkinesia of
normal segments. 
Peak heart rate was significantly higher during dobutamine 
infusion than during exercise test. This finding may be ex- 
plained by the reduced chronotropic reserve related to dener- 
vation after heart transplantation a d has been widely docu- 
mented by several studies (34-36) comparing exercise 
hemodynamic response in patients after heart transplantation 
and in innervated, age-matched control subjects. 
Limitations of the study. The number of patients enrolled 
in the present study was not sufficiently large to establish the 
potential role of dobutamine stress echocardiography in pre- 
dicting short-term prognosis in heart transplant recipients and 
in identifying a subgroup of patients at high risk for major 
cardiac events. Although quantitative coronary angiograms pro- 
vide a better estimate of the magnitude of coronary artery disease 
than nonquantitative angiograms, the use of intravascular ultra- 
sound has been shown to be more reliable in the diagnosis of 
posttransplant coronary artery disease. Hence, it might be useful 
to study such patients with intravascular ultrasound. 
Conclusions. Dobutamine stress echocardiography is a re- 
liable noninvasive technique for detecting postgraft coronary 
artery disease, even when coronary lesions appear to be 
nonsignificant on coronary angiography. It should therefore be 
the test of choice for follow-up of heart ransplant recipients to 
detect postgraft ischemic disease. 
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